A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome
A Phase 1b/2a, first-in-disease, open-label, multiple-ascending dose exploratory study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamic biomarker responses associated with CRN04894 (an adrenocorticotropic hormone \[ACTH\] receptor antagonist) in participants with ACTH-dependent Cushing's syndrome (Cushing's disease or Ectopic ACTH Syndrome \[EAS\])
Trial Details
- NCT ID
- NCT05804669
- Phase
- PHASE1 / PHASE2
- Sponsor
- Crinetics Pharmaceuticals Inc.
- Status
- RECRUITING
- Cancer Type
- Brain Cancer
- Interventions
- Locations (sample)
- Bethesda, Maryland, United States|38.98067,-77.10026
Key Eligibility Criteria
- Adult male or female, aged 18 years or more
- Evidence of chronic 'active' ACTH-dependent Cushing's syndrome
- Evidence of acutely 'active' ACTH-dependent Cushing's syndrome within 10 days of Day 1
- Participants with documented ACTH-dependent Cushing's syndrome taking short-acting steroidogenesis inhibitors (ketoconazole, levoketoconazole, osil…
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Brain Cancer Trials on Trialify →